Dulera costs between $413 and $422 for a single inhaler without insurance, making it one of the pricier combination inhalers on the market. The high price comes down to a few reinforcing factors: no generic version exists, the inhaler combines two drugs in a specialized delivery device, and the manufacturer faces little pressure to lower prices in a market where competitors are similarly expensive.
No Generic Version Is Available
The simplest explanation for Dulera’s price is that it has no generic competition. Despite being FDA-approved since 2010, Dulera is still only sold as a brand-name product. When a drug lacks generic alternatives, the manufacturer can set prices without the downward pressure that copycat products typically create.
Dulera’s non-device patents expired in November 2020, which in theory should have opened the door for generic manufacturers. But combination inhalers are notoriously difficult to replicate. A generic inhaler doesn’t just need to contain the same active ingredients. It also needs to deliver the same particle size, at the same rate, deep enough into the lungs to match the original’s performance. The FDA requires generic inhalers to demonstrate that they work identically to the brand, and meeting that standard for a metered-dose inhaler is a complex, expensive process that discourages many generic manufacturers from even attempting it.
What You’re Actually Paying For
Dulera combines two medications: mometasone (a steroid that reduces airway inflammation) and formoterol (a long-acting bronchodilator that relaxes the muscles around your airways). Combination inhalers cost more than single-ingredient products because they bundle two therapies into one device, and the metered-dose inhaler itself requires precise engineering to deliver consistent doses over 120 actuations.
Here’s the frustrating part: research shows that Dulera doesn’t outperform its competitors. A Bayesian network meta-analysis published in a major respiratory journal found that all steroid/bronchodilator combination inhalers have essentially a “class effect” when it comes to preventing flare-ups. No particular formulation proved better than any other. Medium doses worked just as well as high doses at reducing moderate-to-severe episodes. So you’re not paying a premium for superior results. You’re paying because the product lacks competition and the manufacturer can maintain its price.
How Dulera Compares in Cost
At retail, a single Dulera inhaler (120 doses) runs about $413 for the lower strength and $422 for the higher strength. That’s roughly a month’s supply for most patients using two puffs twice daily. Competitors like Symbicort and Advair carry similar price tags at retail, which means there’s no real incentive for any one manufacturer to drop prices. The entire category of brand-name combination inhalers sits in the $300 to $500 range without insurance, and each company benefits from the others holding firm.
Insurance Often Creates Extra Hurdles
Even with insurance, Dulera can be expensive because many plans place it on a high copay tier or require prior authorization before they’ll cover it. The VA health system, for example, lists Dulera as non-formulary, meaning veterans need a special request and prior approval to get it dispensed. Private insurers often use similar tactics, requiring you to try a preferred inhaler first (called step therapy) before they’ll approve Dulera coverage.
This tier placement reflects the clinical reality that Dulera isn’t meaningfully different from alternatives. Insurers push patients toward whichever combination inhaler they’ve negotiated the best rebate on, and Dulera frequently isn’t that product. If your doctor specifically prescribed Dulera and your plan doesn’t prefer it, you may face a copay of $50 to $100 or more, depending on your benefit design.
Ways to Lower the Cost
Organon, the company that now markets Dulera, offers a copay coupon for commercially insured patients that can reduce out-of-pocket costs. However, these coupons are not available if you’re uninsured or covered by Medicare, Medicaid, or other government programs.
If you don’t have insurance at all, Organon runs a Patient Assistance Program that provides Dulera free of charge to eligible individuals. The program is designed for people whose insurance doesn’t cover the medication or who have no coverage. You’ll need to apply through the program and meet their eligibility criteria, which typically involve income thresholds, though specific cutoffs aren’t publicly listed on their website. Your prescriber’s office can usually start the application process.
Pharmacy discount programs like GoodRx can also shave a meaningful percentage off the retail price, though you’ll still likely pay several hundred dollars. The most effective cost-saving move, if your doctor agrees, is switching to whichever combination inhaler your insurance plan prefers. Since clinical evidence shows these products perform equally well, a formulary-preferred alternative like Symbicort or Advair (which now has a generic, Wixela Inhub) could deliver the same results at a fraction of the cost.